Key facts, as of
As of October 22, 2026, Eli Lilly and Company (LLY) trades at $1,306.69, up 60.8% over the past year. Its 52-week range runs from $806.02 to $1,321.21; the price is 1.1% below that high. It is 1.1% below its all-time high of $1,321.21, reached in October 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +1585.9%, against +312.9% for the S&P 500 (SPY). It sits 20.5% above its 200-day average of $1,084.11, the usual sign of a long-term uptrend. Its 30-day volatility is 28.3% annualized, which we rate medium risk. It has a trailing P/E of 43.9 and a dividend yield of 0.54%. Eli Lilly and Company (LLY) has confirmed its next earnings report for October 29, 2026, before the market opens (date from Yahoo Finance, listed on our October 2026 earnings calendar).
Cite: Portfolio Terminal, "Eli Lilly and Company (LLY) stock analysis", 2026-10-22. https://portfolio-terminal.com/analyse/lly
Where it trades today
trading 97% of the way up its 52-week range
How the price has moved
How far it is from its record
Eli Lilly and Company (LLY) is 1.1% below its all-time high of $1,321.21, reached in October 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +1585.9%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- LLY trades at 43.9x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- Recent realized volatility is running around 28.3%, above the sector norm of 22.0%, so position sizing matters more than usual.
- LLY is in a bullish short-term regime and only 1.1% below its 52-week high, so the question is whether fundamentals can keep pace with that stronger tape.
Portfolio Use Case
- LLY is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in LLY.
- If the short-term trend rolls over while volume fades, the market may stop paying up for momentum before the fundamentals change.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
Methodology
- Price, market cap, beta, yield, and liquidity fields for LLY come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for LLY. Last refresh: Oct 22, 2026, 10:45 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Eli Lilly and Company does
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for…
Employees
50,000
Industry
Drug Manufacturers - General
Headquarters
Indianapolis, United States
What analysts expect
LLY carries a buy consensus from 30 analysts, with an average price target of $1331.55 versus $1306.69 today (+1.9%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
LLY generated $79.67B in trailing revenue (47.7% year over year), with a 33.5% net margin, and $11.07B of free cash flow, against $45.96B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $65.18B | $54.13B | $29.70B | $20.64B | $23.07 | $5.96B |
| 2024 | $45.04B | $36.63B | $17.04B | $10.59B | $11.80 | $414.00M |
| 2023 | $34.12B | $27.04B | $10.32B | $5.24B | $5.83 | -$3.15B |
| 2022 | $28.54B | $21.91B | $8.28B | $6.24B | $6.57 | $4.60B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
LLY is in 21 of the 54 ETFs we track. It weighs most in XLV: 15.7% of the fund, holding #1 of 62.
Famous investors who hold it
LLY is in the latest 13F of 3 of the 15 famous investors we follow. Ray Dalio (Bridgewater Associates) holds the most of it: 0.43% of the portfolio, position #37 of 992, as of Q2 2026.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
LLY beside the healthcare names it is usually measured against.
What the chart is saying
In an uptrend, 1.1% under its 1-year high with no resistance above.
uptrend- Price is 10.2% above its 50-day average and 20.5% above its 200-day.
- RSI at 71 is overbought: strong momentum, and stretched.
- Nothing above has stopped it this year; the nearest floor is $1,224 (-6.4%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is LLY a good investment in 2026?
Eli Lilly and Company trades at a P/E ratio of 43.9, with medium volatility (28.3% annualized). Recent momentum is positive.
What is the risk level of LLY?
Based on 30-day volatility of 28.3%, LLY has MEDIUM risk. Beta of 0.45 indicates lower sensitivity to market movements than average.
Does LLY pay dividends?
Yes, Eli Lilly and Company has a dividend yield of 0.54%.
How far is LLY from its all-time high?
Eli Lilly and Company is 1.1% below its all-time high of $1,321.21, reached in October 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +1585.9%, against +312.9% for the S&P 500 (SPY).
When does Eli Lilly and Company report earnings?
Eli Lilly and Company (LLY) reports its next quarterly earnings on Thursday, October 29, 2026, before the market opens. The company has confirmed the date; it comes from Yahoo Finance's earnings data and is listed on the Portfolio Terminal October 2026 earnings calendar. For that quarter, the analysts' consensus Yahoo Finance reports is earnings of $6.67 per share.
Which ETFs hold LLY?
21 of the 54 popular ETFs we track hold Eli Lilly and Company. The largest weights: XLV (15.7%), VIG (4.10%), MGK (3.11%), IWF (3.04%) and SPYG (2.79%). Measured on each issuer's full holdings file, dated September 25 to October 18, 2026.
How much of VOO is LLY?
1.41%, as of September 30, 2026: LLY is holding #13 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $14.06 in Eli Lilly and Company.
Which famous investors own LLY?
Ray Dalio (0.43% of Bridgewater Associates's 13F), George Soros (0.33% of Soros Fund Management's 13F) and Stanley Druckenmiller (0.28% of Duquesne Family Office's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for LLY?
The average analyst price target for Eli Lilly and Company (LLY) is $1331.55 based on 30 analyst estimates, about 1.9% above the current price of $1306.69. The published range runs from $930.00 to $1600.00.
How much revenue does LLY generate?
Eli Lilly and Company reported $79.67B in trailing twelve-month revenue. Revenue growth is running at 47.7% year over year. Net margin sits at 33.5%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare LLY with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.